Review: transfer for primary angioplasty is better than immediate thrombolysis in acute myocardial infarction.

E. Lang

DOI: https://doi.org/10.7326/acpjc-2004-141-1-001

2004-07-01

ACP Journal Club

Abstract:Source Citation Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108...

What problem does this paper attempt to address?

An RNA Editing Approach for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Monian,P.,Caracta,C.,Shivalila,C.,Lu,G.,Bowman,K.,Byrne,M.,Xie,L.,Desai,J.,Ghosh,A.,Kawamoto,T.,Kandasamy,P.,Lamattina,A.,Liu,F.,Paik,I.-H.,Rheinhardt,J.,Shimizu,M.,Singh,K.,Yang,H.,Narayanan,P.,Shelley Hu,X.,Giangrande,P.,Vargeese,C.

DOI: https://doi.org/10.1183/13993003.congress-2024.oa4551

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Introduction: Severe AATD is caused by a Z mutation in the SERPINA1 gene that leads to misfolding and aggregation of mutant Z-AAT protein in the liver, a decrease in functional serum AAT, and chronic obstructive pulmonary disease (COPD). Objective: We evaluated WVE-006, an investigational N-Acetylgalactosamine (GalNAc)-conjugated RNA editing oligonucleotide, in preclinical models to assess RNA editing as a potential treatment for AATD. Methods: WVE-006, which was designed to correct the Z mutation in SERPINA1 RNA, was administered to transgenic mice that express human mutant SERPINA1. We used hybridization-ELISA to measure concentrations of WVE-006 in liver, Sanger sequencing to quantify RNA editing, ELISA to quantify total serum AAT, mass spectrometry to determine proportion of wild-type AAT and Z-AAT in serum, and an in vitro neutrophil elastase inhibition assay to measure AAT function. Results: WVE-006 induced dose-dependent SERPINA1 editing after a single dose. The highest measured levels of RNA editing (23.6-58.0%) and serum AAT (26.7-40 μM) occurred 3-5 days after dosing. After repeat dosing (10 mg/kg, 7 biweekly doses), WVE-006 directed ~50% editing of the Z transcript and increased total serum AAT protein from ~8 mM to ~30 mM. At baseline, Z-AAT was the only isoform of AAT detected. After treatment, wild-type AAT accounted for ~50% of total serum AAT, and serum from treated mice displayed a ~3-fold improvement in neutrophil elastase inhibition relative to controls. Conclusions: WVE-006 directed editing of SERPINA1 RNA in the mouse liver, which led to the production of functional M-AAT protein, with total AAT in serum reaching levels higher than the 11μM threshold believed to lower risk for COPD.

respiratory system
[Unemployment and health: defective management--sick personnel].

T. Grobe,F. Schwartz

2004-07-01

Pflegezeitschrift

Abstract:
Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in mammalian cells and embryos

Liang Chen,Mengjia Hong,Changming Luan,Hongyi Gao,Gaomeng Ru,Xinyuan Guo,Dujuan Zhang,Shun Zhang,Changwei Li,Jun Wu,Peyton B. Randolph,Alexander A. Sousa,Chao Qu,Yifan Zhu,Yuting Guan,Liren Wang,Mingyao Liu,Bo Feng,Gaojie Song,David R. Liu,Dali Li

DOI: https://doi.org/10.1038/s41587-023-01821-9

IF: 46.9

2023-06-16

Nature Biotechnology

Abstract:Base editors have substantial promise in basic research and as therapeutic agents for the correction of pathogenic mutations. The development of adenine transversion editors has posed a particular challenge. Here we report a class of base editors that enable efficient adenine transversion, including precise A•T-to-C•G editing. We found that a fusion of mouse alkyladenine DNA glycosylase (mAAG) with nickase Cas9 and deaminase TadA-8e catalyzed adenosine transversion in specific sequence contexts. Laboratory evolution of mAAG significantly increased A-to-C/T conversion efficiency up to 73% and expanded the targeting scope. Further engineering yielded adenine-to-cytosine base editors (ACBEs), including a high-accuracy ACBE-Q variant, that precisely install A-to-C transversions with minimal Cas9-independent off-targeting effects. ACBEs mediated high-efficiency installation or correction of five pathogenic mutations in mouse embryos and human cell lines. Founder mice showed 44–56% average A-to-C edits and allelic frequencies of up to 100%. Adenosine transversion editors substantially expand the capabilities and possible applications of base editing technology.

biotechnology & applied microbiology
Cleaning up alpha-1 antitrypsin deficiency related liver disease

Laura Rademacher,Malin Fromme,Pavel Strnad

DOI: https://doi.org/10.1097/MOG.0000000000000919

2023-05-01

Abstract:Purpose of review: Alpha-1 antitrypsin deficiency (AATD) is one of the most common genetic disorders arising due to mutations in alpha-1 antitrypsin (AAT) gene affecting primarily the lung and the liver. This review summarizes the pathophysiology and clinical manifestation of different AATD genotypes and discusses the recent therapeutic developments. The focus is on the severe, rare homozygous Pi∗ZZ and the common heterozygous Pi∗MZ genotype. Recent findings: Pi∗ZZ individuals harbor an up to 20 times higher risk of liver fibrosis and cirrhosis than noncarriers and liver transplantation is currently the only available therapeutic option. AATD constitutes a proteotoxic disorder arising from hepatic AAT accumulation and the currently most promising data come from a phase 2, open-label trial of fazirsiran, a hepatocyte-targeted siRNA. Pi∗MZ subjects display an increased risk of advanced liver disease and at the latter stage, a faster deterioration than individuals without AAT mutation. Summary: Although the fazirsiran data offer a glimpse of hope to AATD patients, a consensus on appropriate study endpoint, a careful patient selection as well as monitoring of long-term safety will be essential for an approval.
In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model

Ramu Gopalappa,MinYoung Lee,Globinna Kim,Eul Sik Jung,Hanahrae Lee,Hye-Yeon Hwang,Jong Geol Lee,Su Jung Kim,Hyun Ju Yoo,Young Hoon Sung,Daesik Kim,In-Jeoung Baek,Hyongbum Henry Kim

DOI: https://doi.org/10.1016/j.ymthe.2024.05.027

2024-07-03

Abstract:X-linked adrenoleukodystrophy (ALD), an inherited neurometabolic disorder caused by mutations in ABCD1, which encodes the peroxisomal ABC transporter, mainly affects the brain, spinal cord, adrenal glands, and testes. In ALD patients, very-long-chain fatty acids (VLCFAs) fail to enter the peroxisome and undergo subsequent β-oxidation, resulting in their accumulation in the body. It has not been tested whether in vivo base editing or prime editing can be harnessed to ameliorate ALD. We developed a humanized mouse model of ALD by inserting a human cDNA containing the pathogenic variant into the mouse Abcd1 locus. The humanized ALD model showed increased levels of VLCFAs. To correct the mutation, we tested both base editing and prime editing and found that base editing using ABE8e(V106W) could correct the mutation in patient-derived fibroblasts at an efficiency of 7.4%. Adeno-associated virus (AAV)-mediated systemic delivery of NG-ABE8e(V106W) enabled robust correction of the pathogenic variant in the mouse brain (correction efficiency: ∼5.5%), spinal cord (∼5.1%), and adrenal gland (∼2%), leading to a significant reduction in the plasma levels of C26:0/C22:0. This established humanized mouse model and the successful correction of the pathogenic variant using a base editor serve as a significant step toward treating human ALD disease.
In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease

Sourav K. Bose,Brandon M. White,Meghana V. Kashyap,Apeksha Dave,Felix R. De Bie,Haiying Li,Kshitiz Singh,Pallavi Menon,Tiankun Wang,Shiva Teerdhala,Vishal Swaminathan,Heather A. Hartman,Sowmya Jayachandran,Prashant Chandrasekaran,Kiran Musunuru,Rajan Jain,David B. Frank,Philip Zoltick,William H. Peranteau

DOI: https://doi.org/10.1038/s41467-021-24443-8

IF: 16.6

2021-07-13

Nature Communications

Abstract:Abstract In utero base editing has the potential to correct disease-causing mutations before the onset of pathology. Mucopolysaccharidosis type I (MPS-IH, Hurler syndrome) is a lysosomal storage disease (LSD) affecting multiple organs, often leading to early postnatal cardiopulmonary demise. We assessed in utero adeno-associated virus serotype 9 (AAV9) delivery of an adenine base editor (ABE) targeting the Idua G→A (W392X) mutation in the MPS-IH mouse, corresponding to the common IDUA G→A (W402X) mutation in MPS-IH patients. Here we show efficient long-term W392X correction in hepatocytes and cardiomyocytes and low-level editing in the brain. In utero editing was associated with improved survival and amelioration of metabolic, musculoskeletal, and cardiac disease. This proof-of-concept study demonstrates the possibility of efficiently performing therapeutic base editing in multiple organs before birth via a clinically relevant delivery mechanism, highlighting the potential of this approach for MPS-IH and other genetic diseases.

multidisciplinary sciences
Improved specificity and efficacy of base-editing therapies with hybrid guide RNAs

Madelynn N. Whittaker,Dominique L. Brooks,Aidan Quigley,Ishaan Jindal,Hooda Said,Ping Qu,Josh Zhiyong Wang,Rebecca C. Ahrens-Nicklas,Kiran Musunuru,Mohamad-Gabriel Alameh,William H. Peranteau,Xiao Wang

DOI: https://doi.org/10.1101/2024.04.22.590531

2024-06-16

Abstract:Phenylketonuria (PKU), hereditary tyrosinemia type 1 (HT1), and mucopolysaccharidosis type 1 (MPSI) are autosomal recessive disorders linked to the phenylalanine hydroxylase ( ) gene, fumarylacetoacetate hydrolase ( ) gene, and alpha-L-iduronidase ( ) gene, respectively. Potential therapeutic strategies to ameliorate disease include corrective editing of pathogenic variants in the and and, as a variant-agnostic approach, inactivation of the 4-hydroxyphenylpyruvate dioxygenase ( ) gene, a modifier of HT1, via adenine base editing. Here we evaluated the off-target editing profiles of therapeutic lead guide RNAs (gRNAs) that, when combined with adenine base editors correct the recurrent P281L variant, R408W variant, or W402X variant or disrupt the gene in human hepatocytes. To mitigate off-target mutagenesis, we systematically screened hybrid gRNAs with DNA nucleotide substitutions. Comprehensive and variant-aware specificity profiling of these hybrid gRNAs reveal dramatically reduced off-target editing and reduced bystander editing. Lastly, in a humanized P281L mouse model, we showed that when formulated in lipid nanoparticles (LNPs) with adenine base editor mRNA, selected hybrid gRNAs revert the PKU phenotype, substantially enhance on-target editing, and reduce bystander editing . These studies highlight the utility of hybrid gRNAs to improve the safety and efficacy of base-editing therapies.

Molecular Biology
Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Luzi Yang,Zhanzhao Liu,Jinhuan Sun,Zhan Chen,Fei Gao,Yuxuan Guo

DOI: https://doi.org/10.1111/jcmm.18145

2024-02-10

Journal of Cellular and Molecular Medicine

Abstract:Abstract Base editors are emerging as powerful tools to correct single‐nucleotide variants and treat genetic diseases. In particular, the adenine base editors (ABEs) exhibit robust and accurate adenine‐to‐guanidine editing capacity and have entered the clinical stage for cardiovascular therapy. Despite the tremendous progress using ABEs to treat heart diseases, a standard technical route toward successful ABE‐based therapy remains to be fully established. In this study, we harnessed adeno‐associated virus (AAV) and a mouse model carrying the cardiomyopathy‐causing Lmna c.1621C > T mutation to demonstrate key steps and concerns in designing a cardiac ABE experiment in vivo. We found DeepABE as a reliable deep‐learning‐based model to predict ABE editing outcomes in the heart. Screening of sgRNAs for a Cas9 mutant with relieved protospacer adjacent motif (PAM) allowed the reduction of bystander editing. The ABE editing efficiency can be significantly enhanced by modifying the TadA and Cas9 variants, which are core components of ABEs. The ABE systems can be delivered into the heart via either dual AAV or all‐in‐one AAV vectors. Together, this study showcased crucial technical considerations in designing an ABE system for the heart and pointed out major challenges in further improvement of this new technology for gene therapy.

cell biology,medicine, research & experimental
Age-specific profiles of tissue-level composition and mechanical properties in murine cortical bone.

M. Raghavan,Nadder D. Sahar,D. Kohn,M. Morris

DOI: https://doi.org/10.1016/j.bone.2011.12.026

IF: 4.626

2012-04-01

Bone

Abstract:
Alpha-1 Antitrypsin—A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis

Hilary Humphreys,Alison M.D. Hunt,Arlene M.A. Glasgow,Catherine M. Greene

DOI: https://doi.org/10.3390/ijms21030836

IF: 5.6

2020-01-28

International Journal of Molecular Sciences

Abstract:Cystic fibrosis (CF) is an autosomal recessive genetic disorder arising from mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Disruption to normal ion homeostasis in the airway results in impaired mucociliary clearance, leaving the lung more vulnerable to recurrent and chronic bacterial infections. The CF lung endures an excess of neutrophilic inflammation, and whilst neutrophil serine proteases are a crucial part of the innate host defence to infection, a surplus of neutrophil elastase (NE) is understood to create a net destructive effect. Alpha-1 antitrypsin (A1AT) is a key antiprotease in the control of NE protease activity but is ineffective in the CF lung due to the huge imbalance of NE levels. Therapeutic strategies to boost levels of protective antiproteases such as A1AT in the lung remain an attractive research strategy to limit the damage from excess protease activity. microRNAs are small non-coding RNA molecules that bind specific cognate sequences to inhibit expression of target mRNAs. The inhibition of miRNAs which target the SERPINA1 (A1AT-encoding gene) mRNA represents a novel therapeutic approach for CF inflammation. This could involve the delivery of antagomirs that bind and sequester the target miRNA, or target site blockers that bind miRNA recognition elements within the target mRNA to prevent miRNA interaction. Therefore, miRNA targeted therapies offer an alternative strategy to drive endogenous A1AT production and thus supplement the antiprotease shield of the CF lung.

biochemistry & molecular biology,chemistry, multidisciplinary
Directed evolution of adenine base editors with increased activity and therapeutic application

Nicole M. Gaudelli,Dieter K. Lam,Holly A. Rees,Noris M. Solá-Esteves,Luis A. Barrera,David A. Born,Aaron Edwards,Jason M. Gehrke,Seung-Joo Lee,Alexander J. Liquori,Ryan Murray,Michael S. Packer,Conrad Rinaldi,Ian M. Slaymaker,Jonathan Yen,Lauren E. Young,Giuseppe Ciaramella

DOI: https://doi.org/10.1038/s41587-020-0491-6

IF: 46.9

2020-04-13

Nature Biotechnology

Abstract:The foundational adenine base editors (for example, ABE7.10) enable programmable A•T to G•C point mutations but editing efficiencies can be low at challenging loci in primary human cells. Here we further evolve ABE7.10 using a library of adenosine deaminase variants to create ABE8s. At NGG protospacer adjacent motif (PAM) sites, ABE8s result in ~1.5× higher editing at protospacer positions A5–A7 and ~3.2× higher editing at positions A3–A4 and A8–A10 compared with ABE7.10. Non-NGG PAM variants have a ~4.2-fold overall higher on-target editing efficiency than ABE7.10. In human CD34+ cells, ABE8 can recreate a natural allele at the promoter of the γ-globin genes HBG1 and HBG2 with up to 60% efficiency, causing persistence of fetal hemoglobin. In primary human T cells, ABE8s achieve 98–99% target modification, which is maintained when multiplexed across three loci. Delivered as messenger RNA, ABE8s induce no significant levels of single guide RNA (sgRNA)-independent off-target adenine deamination in genomic DNA and very low levels of adenine deamination in cellular mRNA.

biotechnology & applied microbiology
Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

Nélia Abreu,Vítor Magno Pereira,Madalena Pestana,Luís Jasmins

DOI: https://doi.org/10.1159/000528809

2023-02-02

GE Portuguese Journal of Gastroenterology

Abstract:Alpha-1 antitrypsin deficiency (AATD) is one of the most common genetic diseases and is caused by mutations in the SERPINA1 gene. The homozygous Pi*Z variant is responsible for the majority of the classic severe form of alpha-1 antitrypsin deficiency, which is characterized by markedly decreased levels of serum alpha-1 antitrypsin (AAT) with a strong predisposition to lung and liver disease. The diagnosis and early treatment of AATD-associated liver disease are challenges in clinical practice. In this review, the authors aim to summarize the current evidence of the non-invasive methods in the assessment of liver fibrosis, as well as to elucidate the main therapeutic strategies under investigation that may emerge in the near future.
Oxidation‐resistant and Thermostable Forms of Alpha‐1 Antitrypsin from Escherichia Coli Inclusion Bodies

Wei Zhu,Lanfen Li,Mingjing Deng,Bo Wang,Mengfei Li,Guofang Ding,Zuisu Yang,Dan Medynski,Xiaotao Lin,Ying Ouyang,Jirui Lin,Luyuan Li,Xinli Lin

DOI: https://doi.org/10.1002/2211-5463.12515

2018-01-01

FEBS Open Bio

Abstract:Native α1‐antitrypsin (AAT) is a 52‐kDa glycoprotein that acts as an antiprotease and is the physiological inhibitor of neutrophil serine proteases. The main function of AAT is to protect the lung from proteolytic damage induced by inflammation. AAT deficiency (AATD) is a codominant autosomal disorder caused by pathogenic mutations in SERPINA1 gene, leading to reduced levels of serum AAT. The deficiency is known to increase the risk of pulmonary emphysema and chronic obstructive pulmonary disease as a consequence of proteolytic imbalance induced by inflammation, associated in many instances with cigarette smoking and other environmental hazards. Currently, the available therapy for lung disease associated with AATD is serum purified human AAT injected into patients on a weekly basis. It would be advantageous to replace serum‐derived AAT with a recombinant version which is stable and resistant to oxidation. We have expressed AAT in Escherichia coli as inclusion bodies and developed a highly efficient refolding and purification process. We engineered a series of mutant forms of AAT to achieve enhance thermostability and oxidation resistance. Moreover, we synthesized an active form of AAT via cysteine‐pegylation to achieve a markedly extended half‐life in vivo. The resulting molecule, which retains comparable activity to the wild‐type form, is expected to be an improved therapeutic agent for treating hereditary emphysema. In addition, the molecule may also be used to treat other types of emphysema caused by smoking, cystic fibrosis, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease.
Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells

Chloe L Christensen,Shih-Hsin Kan,Perla Andrade-Heckman,Allisandra K Rha,Jerry F Harb,Raymond Y Wang

DOI: https://doi.org/10.1016/j.omtn.2024.102220

2024-05-21

Abstract:Infantile-onset Pompe disease (IOPD) results from pathogenic variants in the GAA gene, which encodes acid α-glucosidase. The correction of pathogenic variants through genome editing may be a valuable one-time therapy for PD and improve upon the current standard of care. We performed adenine base editing in human dermal fibroblasts harboring three transition nonsense variants, c.2227C>T (p.Q743∗; IOPD-1), c.2560C>T (p.R854∗; IOPD-2), and c.2608C>T (p.R870∗; IOPD-3). Up to 96% adenine deamination of target variants was observed, with minimal editing across >50 off-target sites. Post-base editing, expressed GAA protein was up to 0.66-fold normal (unaffected fibroblasts), an improvement over affected fibroblasts wherein GAA was undetectable. GAA enzyme activity was between 81.91 ± 13.51 and 129.98 ± 9.33 units/mg protein at 28 days post-transfection, which falls within the normal range (50-200 units/mg protein). LAMP2 protein was significantly decreased in the most robustly edited cell line, IOPD-3, indicating reduced lysosomal burden. Taken together, the findings reported herein demonstrate that base editing results in efficacious adenine deamination, restoration of GAA expression and activity, and reduction in lysosomal burden in the most robustly edited cells. Future work will assess base editing outcomes and the impact on Pompe pathology in two mouse models, Gaa c.2227C>T and Gaa c.2560C>T.
Novel Transgenic Humanized Alpha-1 Antitrypsin Deficiency Mouse Model on Murine SERPINA1 Null Background

Regina Oshins,Alek M Aranyos,Skylar Grey,Naweed Mohammad,Yuanqing Lu,Jorge E Lascano,Tammy Flagg,Karina Serban,Mark Brantly,Nazli Khodayari

DOI: https://doi.org/10.1101/2024.10.11.617858

2024-10-11

Abstract:Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder caused by accumulation of misfolded α-1 antitrypsin within hepatocytes. AATD patients are prone to develop liver disease that remains undiagnosed until the late stages of the disease. Due to challenges in manipulating the α-1 antitrypsin genes in mice, determining a true loss of function of α-1 antitrypsin in previous AATD mouse models has been challenging. Here, we report generation and liver characterization of a new humanized transgenic mouse model for AATD with a background of a CRISPR-Cas9 generated SERPINA1-null mouse. Male and female transgenic mice for normal (Pi*M) and mutant (Pi*Z) variants of human α-1 antitrypsin at 4-6 months of age were subjected to this study. The accumulation of human α-1 antitrypsin in the hepatocytes and fibrotic features of the liver were monitored by performing an in vivo study. We demonstrate a strong liver phenotype satisfying clinically relevant manifestations of liver pathology associated with AATD, including hepatic accumulation of human α-1 antitrypsin globules, liver deposition of extracellular matrix proteins, hepatic ER stress, and liver fibrosis in Pi*Z mice, in addition to mild systemic inflammation. In addition to major phenotypic criteria of AATD-associated liver fibrosis, accompanying single-nucleus RNA-seq data demonstrate activation of pathways associated with liver metabolic changes, inflammation, and regeneration. Data from this study suggest our humanized transgenic AATD mouse model could provide a suitable model to study α-1 antitrypsin loss of function, replicate the pathophysiology of AATD associated liver disease, and evaluate therapeutic reagents against this disease.

Molecular Biology
Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors

Sateesh Krishnamurthy,Soumba Traore,Ashley L Cooney,Christian M Brommel,Katarina Kulhankova,Patrick L Sinn,Gregory A Newby,David R Liu,Paul B McCray,Patrick L Sinn,Gregory A Newby,David R Liu,Paul B McCray

DOI: https://doi.org/10.1093/nar/gkab788

IF: 14.9

2021-09-14

Nucleic Acids Research

Abstract:Abstract Mutations in the CFTR gene that lead to premature stop codons or splicing defects cause cystic fibrosis (CF) and are not amenable to treatment by small-molecule modulators. Here, we investigate the use of adenine base editor (ABE) ribonucleoproteins (RNPs) that convert A•T to G•C base pairs as a therapeutic strategy for three CF-causing mutations. Using ABE RNPs, we corrected in human airway epithelial cells premature stop codon mutations (R553X and W1282X) and a splice-site mutation (3849 + 10 kb C > T). Following ABE delivery, DNA sequencing revealed correction of these pathogenic mutations at efficiencies that reached 38–82% with minimal bystander edits or indels. This range of editing was sufficient to attain functional correction of CFTR-dependent anion channel activity in primary epithelial cells from CF patients and in a CF patient-derived cell line. These results demonstrate the utility of base editor RNPs to repair CFTR mutations that are not currently treatable with approved therapeutics.

biochemistry & molecular biology
Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema

Florie Borel,Huaming Sun,Marina Zieger,Andrew Cox,Brynn Cardozo,Weiying Li,Gabriella Oliveira,Airiel Davis,Alisha Gruntman,Terence R. Flotte,Michael H. Brodsky,Andrew M. Hoffman,Mai K. Elmallah,Christian Mueller

DOI: https://doi.org/10.1073/pnas.1713689115

IF: 11.1

2018-02-16

Proceedings of the National Academy of Sciences

Abstract:Significance Chronic obstructive pulmonary disease affects 10% of the worldwide population, and the leading genetic cause is a genetic disease, α-1 antitrypsin (AAT) deficiency. Humans have only one gene that codes for the AAT protein, but mice have up to six, which made it impossible for decades to create a mouse model of the disease. Here we succeeded in creating this mouse model using CRISPR technology to target all of the mouse genes at once. Importantly, this mouse model spontaneously develops lung disease and recapitulates many aspects of the human disease. We anticipate that this model will be highly relevant not only to the preclinical development of therapeutics for AAT deficiency, but also to emphysema and smoking research.
Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

Carmen Mazzuca,Laura Vitiello,Silvia Travaglini,Fatima Maurizi,Panaiotis Finamore,Simona Santangelo,Amelia Rigon,Marta Vadacca,Silvia Angeletti,Simone Scarlata

DOI: https://doi.org/10.3389/fimmu.2024.1443297

2024-08-19

Abstract:α -1 antitrypsin (A1AT) is a 52 kDa acute-phase glycoprotein belonging to the serine protease inhibitor superfamily (SERPIN). It is primarily synthesized by hepatocytes and to a lesser extent by monocytes, macrophages, intestinal epithelial cells, and bronchial epithelial cells. A1AT is encoded by SERPINA1 locus, also known as PI locus, highly polymorphic with at least 100 allelic variants described and responsible for different A1AT serum levels and function. A1AT inhibits a variety of serine proteinases, but its main target is represented by Neutrophil Elastase (NE). However, recent attention has been directed towards its immune-regulatory and homeostatic activities. A1AT exerts immune-regulatory effects on different cell types involved in innate and adaptive immunity. Additionally, it plays a role in metal and lipid metabolism, contributing to homeostasis. An adequate comprehension of these mechanisms could support the use of A1AT augmentation therapy in many disorders characterized by a chronic immune response. The aim of this review is to provide an up-to-date understanding of the molecular mechanisms and regulatory pathways responsible for immune-regulatory and homeostatic activities of A1AT. This knowledge aims to support the use of A1AT in therapeutic applications. Furthermore, the review summarizes the current state of knowledge regarding the application of A1AT in clinical and laboratory settings human and animal models.
Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases

Colin Walsh,Sha Jin

DOI: https://doi.org/10.3390/cells13121052

IF: 6

2024-06-19

Cells

Abstract:Human induced pluripotent stem cell (iPSC) and CRISPR-Cas9 gene-editing technologies have become powerful tools in disease modeling and treatment. By harnessing recent biotechnological advancements, this review aims to equip researchers and clinicians with a comprehensive and updated understanding of the evolving treatment landscape for metabolic and genetic disorders, highlighting how iPSCs provide a unique platform for detailed pathological modeling and pharmacological testing, driving forward precision medicine and drug discovery. Concurrently, CRISPR-Cas9 offers unprecedented precision in gene correction, presenting potential curative therapies that move beyond symptomatic treatment. Therefore, this review examines the transformative role of iPSC technology and CRISPR-Cas9 gene editing in addressing metabolic and genetic disorders such as alpha-1 antitrypsin deficiency (A1AD) and glycogen storage disease (GSD), which significantly impact liver and pulmonary health and pose substantial challenges in clinical management. In addition, this review discusses significant achievements alongside persistent challenges such as technical limitations, ethical concerns, and regulatory hurdles. Future directions, including innovations in gene-editing accuracy and therapeutic delivery systems, are emphasized for next-generation therapies that leverage the full potential of iPSC and CRISPR-Cas9 technologies.

cell biology
Emerging Concepts and Human Trials in Alpha-1-Antitrypsin Deficiency Liver Disease

Jeffrey Teckman

DOI: https://doi.org/10.1055/s-0037-1602586

2017-05-01

Seminars in Liver Disease

Abstract:Abstract In α-1-antitrypsin (AAT) deficiency, individuals homozygous for the AAT mutant Z gene synthesize large quantities of mutant Z protein in the liver, which folds improperly during biogenesis and is retained within the hepatocytes rather than appropriated secreted. This accumulation of mutant Z protein triggers an intracellular injury cascade causing cell death in the population of hepatocytes with the largest accumulations of Z protein. Hepatocellular proliferation, hepatic fibrosis, and hepatocellular cancer in some individuals can be the result. New insights from basic science studies have now allowed the application of new biotechnologies to this previously untreatable disease. Specifically, drugs designed to accelerate the intracellular removal of the mutant Z protein (autophagy enhancers) and siRNA strategies designed to shut down synthesis of the toxic, mutant Z protein, are now in human trials. Other approaches, such as gene correction, cell therapy, and antifibrotic drugs are in preclinical development.

gastroenterology & hepatology

Review: transfer for primary angioplasty is better than immediate thrombolysis in acute myocardial infarction.

An RNA Editing Approach for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

[Unemployment and health: defective management--sick personnel].

Adenine transversion editors enable precise, efficient A•T-to-C•G base editing in mammalian cells and embryos

Cleaning up alpha-1 antitrypsin deficiency related liver disease

In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model

In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease

Improved specificity and efficacy of base-editing therapies with hybrid guide RNAs

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Age-specific profiles of tissue-level composition and mechanical properties in murine cortical bone.

Alpha-1 Antitrypsin—A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis

Directed evolution of adenine base editors with increased activity and therapeutic application

Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

Oxidation‐resistant and Thermostable Forms of Alpha‐1 Antitrypsin from Escherichia Coli Inclusion Bodies

Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells

Novel Transgenic Humanized Alpha-1 Antitrypsin Deficiency Mouse Model on Murine SERPINA1 Null Background

Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors

Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema

Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases

Emerging Concepts and Human Trials in Alpha-1-Antitrypsin Deficiency Liver Disease